Aging and Parkinson's disease: Different sides of the same coin?

Abstract

Despite abundant epidemiological evidence in support of aging as the primary risk factor for PD, biological correlates of a connection have been elusive. In this article, we address the following question: does aging represent biology accurately characterized as pre‐PD? We present evidence from our work on midbrain dopamine neurons of aging nonhuman primates that demonstrates that markers of known correlates of dopamine neuron degeneration in PD, including impaired proteasome/lysosome function, oxidative/nitrative damage, and inflammation, all increase with advancing age and are exaggerated in the ventral tier substantia nigra dopamine neurons most vulnerable to degeneration in PD. Our findings support the view that aging‐related changes in the dopamine system approach the biological threshold for parkinsonism, actively producing a vulnerable pre‐parkinsonian state. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

References 67

1. 1.

   Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin. 1996;14:317-335.

   Not in our library10.1016/s0733-8619(05)70259-0

2. 2.

   Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkin-sonian signs and associated mortality in a community population of older people. N Engl J Med. 1996;334:71-76.

   Not in our library10.1056/nejm199601113340202

3. 3.

   Calne DB, Langston JW. Aetiology of Parkinson’s disease. Lancet. 1983;2:1457-1479.

   Not in our library10.1016/s0140-6736(83)90802-4

4. 4.

   Sulzer D. Multiple hit hypothesis for dopamine neuron loss in Parkinson’s disease. Trends Neurosci. 2007;30:244-250.

   Not in our library10.1016/j.tins.2007.03.009

5. 5.

   Collier TJ, Kanaan NM, Kordower JH. Ageing as a primary risk factor for Parkinson’s disease: evidence from studies of non-human primates. Nature Rev Neurosci. 2011;12:359-366.

   Not in our library10.1038/nrn3039

6. 6.

   Olanow CW, Kordower JH. Modeling Parkinson’s disease. Ann Neurol. 2009;66:432-436.

   Not in our library10.1002/ana.21832

7. 7.

   Collier TJ, Sortwell CE, Daley BF. Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: An argument for neurotrophic supplementation. J Neurosci. 1999;19:5563-5573.

   Not in our library10.1523/jneurosci.19-13-05563.1999

8. 8.

   Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29:1583-1590.

   Not in our library10.1002/mds.25945

9. 9.

   Diedrich NJH, Moore CG, Leurgans SE, Chmura TA, Goetz CG. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol. 2003;60:529-533.

   Not in our library10.1001/archneur.60.4.529

10. 10.

    Hely MA, Morris JG, Reid WG, et al. Age at onset: the major determinant of outcome in Parkinson’s disease. Acta Neurol Scand. 1995;92:455-463.

    Not in our library10.1111/j.1600-0404.1995.tb00480.x

11. 11.

    Jankovic J, Kapadia AS. Functional decline in Parkinson’s disease. Arch Neurol. 2001;58:1611-1615.

    Not in our library10.1001/archneur.58.10.1611

12. 12.

    Collier TJ, O’Malley JO, Rademacher DJ, et al. Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration. Neurobiol Dis. 2015;77:191-203.

    Not in our library10.1016/j.nbd.2015.03.005

13. 13.

    Kordower JH, Goetz CG, Chu Y, et al. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017;81:46-57.

    Not in our library10.1002/ana.24820

14. 14.

    Stark AK, Pakkenberg B. Histological changes of the dopaminergic nigrostriatal system in aging. Cell Tissue Res. 2004;318:81-92.

    Not in our library10.1007/s00441-004-0972-9

15. 15.

    Darbin O. The aging striatal dopamine function. Parkinsonism Relat Disord. 2012;18:426-432.

    Not in our library10.1016/j.parkreldis.2011.11.025

16. 16.

    Seidler RD, Bernard JA, Burutolu TB, et al. Motor control and aging: links to age-related brain structural, functional, and biochemical effects. Neurosci Biobehav Rev. 2010;34:721-733.

    Not in our library10.1016/j.neubiorev.2009.10.005

17. 17.

    Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.

    Not in our library10.1093/brain/114.5.2283

18. 18.

    Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal sub-populations of the substantia nigra, and differential cell death in Parkinson’s disease. J Neurol Neurosurg Psychiatr. 1991;54:388-396.

    Not in our library10.1136/jnnp.54.5.388

19. 19.

    Barbeau A. Etiology of Parkinson’s disease: a research strategy. Can J Neurol Sci. 1984;11:24-28.

    Not in our library10.1017/s0317167100045273

20. 20.

    Mann DMA, Yates PO. Pathogenesis of Parkinson’s disease. Arch Neurol. 1982;39:545-549.

    Not in our library10.1001/archneur.1982.00510210015004

21. 21.

    Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr 1 in Parkinson’s disease and related disorders. J Comp Neurol. 2006;494:495-514.

    Not in our library10.1002/cne.20828

22. 22.

    Kastner A, Hirsch EC, Herrero MT, Javoy-Agid F, Agid Y. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson’s and Alzheimer’s disease. J Neurochem. 1993;61:1024-1034.

    Not in our library10.1111/j.1471-4159.1993.tb03616.x

23. 23.

    Miller GW, Erickson JD, Perez JT, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson’s disease. Exp Neurol. 1999;156:138-148.

    Not in our library10.1006/exnr.1998.7008

24. 24.

    Andersen AH, Zhang Z, Zhang M, Gash DM, Avison MJ. Age-associated changes in rhesus CNS composition identified by MRI. Brain Res. 1999;829:90-98.

    Not in our library10.1016/s0006-8993(99)01343-8

25. 25.

    Collier TJ, Lipton J, Daley BF, et al. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in non-human primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis. 2007;26:56-65.

    Not in our library10.1016/j.nbd.2006.11.013

26. 26.

    Irwin I, DeLanney LE, McNeill T, et al. Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration. 1994;3:251-265.

    Not in our library

27. 27.

    McCormack AL, Di Monte DA, Delfani K, et al. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol. 2004;471:387-395.

    Not in our library10.1002/cne.20036

28. 28.

    Pakkenberg H, Andersen BB, Burns RS, Pakkenberg BA. A stereological study of substantia nigra in young and old rhesus monkeys. Brain Res. 1995;693:201-206.

    Not in our library10.1016/0006-8993(95)00678-j

29. 29.

    Kanaan NM, Kordower JH, Collier TJ. Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol. 2007;502:683-700.

    Not in our library10.1002/cne.21333

30. 30.

    Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839-840.

    Not in our library10.1038/42166

31. 31.

    Goldman JE, Yen SH, Chiu FC, Peress NS. Lewy bodies of Parkinson’s disease contain neurofilament antigens. Science. 1983;221:1082-1084.

    Not in our library10.1126/science.6308771

32. 32.

    Zhu JH, Kulich SM, Oury TD, Chu CT. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am J Pathol. 2002;161:2087-2098.

    Not in our library10.1016/s0002-9440(10)64487-2

33. 33.

    Shimura H, Hattori N, Kubo Si, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000;25:302-305.

    Not in our library10.1038/77060

34. 34.

    Eiyama A, Okamoto K. PINK1/Parkin-mediated mitophagy in mammalian cells. Cuur Opin Cell Biol. 2015;33:95-101.

    Not in our library10.1016/j.ceb.2015.01.002

35. 35.

    Duncan TM, Fon EA. The three ‘P”s of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes Dev. 2015;29:989-999.

    Not in our library10.1101/gad.262758.115

36. 36.

    Ulfig N. Altered lipofuscin pigmentation in the basal nucleus (Meynert) in Parkinson’s disase. Neurosci Res. 1989;6:456-462.

    Not in our library10.1016/0168-0102(89)90007-2

37. 37.

    McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol. 2003;179:38-46.

    Not in our library10.1006/exnr.2002.8050

38. 38.

    McNaught KS, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett. 2002;326:155-158.

    Not in our library10.1016/s0304-3940(02)00296-3

39. 39.

    Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009;35:385-398.

    Not in our library10.1016/j.nbd.2009.05.023

40. 40.

    Brunk UT, Terman A. The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as a result of imperfect autophagocytosis. Eur J Biochem. 2002;269:1996-2002.

    Not in our library10.1046/j.1432-1033.2002.02869.x

Cited by papers we hold 7

• Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution · 2024
  Corrected
• The Beneficial Roles of SIRT1 in Neuroinflammation-Related Diseases · 2020
  No notice
• The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease · 2019
  No notice
• Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease · 2019
  No notice
• Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration · 2018
  Corrected
• The Kaleidoscope of Microglial Phenotypes · 2018
  No notice
• Tenuigenin protects dopaminergic neurons from inflammation via suppressing NLRP3 inflammasome activation in microglia · 2017
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.